Royalty Pharma Plc (RPRX) stock news · P/E 33, rev $2.38B
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
This RPRX news page leads with what Royalty Pharma Plc filed — not a scraped headline mill.
No cached 8-K sentence for RPRX yet. We will not pad this page with generic market recap.
Latest reported RPRX revenue for 2025-12-31 was $2.38B. Net income was $770.9M. Revenue was up 5.1% from 2024-12-31 to 2025-12-31. RPRX currently screens at market cap $20.45B and trailing P/E 32.6.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the RPRX stock page; for the tape open the quote page.
RPRX stock news FAQ
What are RPRX's latest revenue and net income?
Latest cached Royalty Pharma Plc (RPRX) revenue for Dec 31, 2025 was $2.38B. Net income was $770.9M. Statements: https://lician.com/financials/rprx
How did RPRX revenue change from the prior cached period?
Cached Royalty Pharma Plc (RPRX) revenue was up 5.1% from $2.26B (Dec 31, 2024) to $2.38B (Dec 31, 2025). Statements: https://lician.com/financials/rprx
What is RPRX's P/E ratio?
Royalty Pharma Plc (RPRX) trailing P/E is 32.6 on the latest cached fundamentals snapshot.
What is RPRX's market cap?
Royalty Pharma Plc (RPRX) market cap is $20.45B on the latest cached fundamentals snapshot.
What kind of company is RPRX?
Royalty Pharma Plc (RPRX) is a biotechnology company listed on US.
Where is RPRX stock news listed?
Cached stock news for Royalty Pharma Plc (RPRX) is listed at https://lician.com/news/rprx. Filings: https://lician.com/sec/rprx
Not investment advice.